Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Buy
53
ZBH Quote, Financials, Valuation and Earnings
Last price:
$98.72
Seasonality move
:
-0.03%
Day range:
$97.53 - $99.70
52-week range:
$84.59 - $114.44
Dividend yield:
0.97%
P/E ratio:
27.84x
P/S ratio:
2.38x
P/B ratio:
1.54x
Volume:
1.8M
Avg. volume:
2.5M
1-year change:
-4.71%
Market cap:
$19.6B
Revenue:
$8.2B
EPS (TTM):
$3.55
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
ZBH
Zimmer Biomet Holdings, Inc.
|
$2.2B | $2.40 | 8.14% | 103.68% | $102.65 |
|
ISRG
Intuitive Surgical, Inc.
|
$2.8B | $2.27 | 16.31% | 10.87% | $611.82 |
|
NMTC
NeuroOne Medical Technologies Corp.
|
$2.7M | -- | 75.83% | -57.14% | $2.30 |
|
NTRB
Nutriband, Inc.
|
$765K | -$0.17 | 4.52% | -54.85% | $15.00 |
|
SYK
Stryker Corp.
|
$7.1B | $4.40 | 8.35% | 77.07% | $424.40 |
|
TNDM
Tandem Diabetes Care, Inc.
|
$277.2M | -$0.09 | 3.86% | -77.52% | $27.27 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
ZBH
Zimmer Biomet Holdings, Inc.
|
$98.75 | $102.65 | $19.6B | 27.84x | $0.24 | 0.97% | 2.38x |
|
ISRG
Intuitive Surgical, Inc.
|
$504.05 | $611.82 | $179B | 64.00x | $0.00 | 0% | 18.17x |
|
NMTC
NeuroOne Medical Technologies Corp.
|
$0.68 | $2.30 | $34.3M | -- | $0.00 | 0% | 3.51x |
|
NTRB
Nutriband, Inc.
|
$4.43 | $15.00 | $53.9M | -- | $0.00 | 0% | 22.11x |
|
SYK
Stryker Corp.
|
$380.23 | $424.40 | $145.5B | 45.27x | $0.88 | 0.89% | 5.85x |
|
TNDM
Tandem Diabetes Care, Inc.
|
$24.57 | $27.27 | $1.7B | -- | $0.00 | 0% | 1.63x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
ZBH
Zimmer Biomet Holdings, Inc.
|
37.91% | -0.699 | 43.48% | 0.93x |
|
ISRG
Intuitive Surgical, Inc.
|
0.95% | 0.941 | 0.08% | 3.73x |
|
NMTC
NeuroOne Medical Technologies Corp.
|
3.58% | 2.768 | 0.62% | 4.95x |
|
NTRB
Nutriband, Inc.
|
3.31% | 2.122 | 0.32% | 7.07x |
|
SYK
Stryker Corp.
|
42.19% | 0.338 | 12.42% | 1.07x |
|
TNDM
Tandem Diabetes Care, Inc.
|
74.33% | 1.906 | 30.15% | 1.92x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
ZBH
Zimmer Biomet Holdings, Inc.
|
$1.3B | $282.9M | 3.53% | 5.61% | 12.61% | $358.3M |
|
ISRG
Intuitive Surgical, Inc.
|
$1.9B | $864.3M | 16.53% | 16.59% | 30.16% | $730M |
|
NMTC
NeuroOne Medical Technologies Corp.
|
$1.6M | -$1.7M | -125.68% | -132.79% | -59.02% | -$3.2M |
|
NTRB
Nutriband, Inc.
|
$63K | -$3.9M | -159.71% | -164.64% | -1121.15% | -$1.8M |
|
SYK
Stryker Corp.
|
$4.5B | $2B | 8.59% | 15.17% | 27.74% | $1.9B |
|
TNDM
Tandem Diabetes Care, Inc.
|
$167.5M | $8.3M | -32.45% | -121.88% | 2.86% | $3.1M |
Zimmer Biomet Holdings, Inc. vs. Competitors
-
Which has Higher Returns ZBH or ISRG?
Intuitive Surgical, Inc. has a net margin of 6.15% compared to Zimmer Biomet Holdings, Inc.'s net margin of 27.89%. Zimmer Biomet Holdings, Inc.'s return on equity of 5.61% beat Intuitive Surgical, Inc.'s return on equity of 16.59%.
Company Gross Margin Earnings Per Share Invested Capital ZBHZimmer Biomet Holdings, Inc.56.23% $0.70 $20.5B ISRGIntuitive Surgical, Inc.66.41% $2.21 $18.1B -
What do Analysts Say About ZBH or ISRG?
Zimmer Biomet Holdings, Inc. has a consensus price target of $102.65, signalling upside risk potential of 3.95%. On the other hand Intuitive Surgical, Inc. has an analysts' consensus of $611.82 which suggests that it could grow by 21.38%. Given that Intuitive Surgical, Inc. has higher upside potential than Zimmer Biomet Holdings, Inc., analysts believe Intuitive Surgical, Inc. is more attractive than Zimmer Biomet Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ZBHZimmer Biomet Holdings, Inc.6 17 2 ISRGIntuitive Surgical, Inc.16 10 1 -
Is ZBH or ISRG More Risky?
Zimmer Biomet Holdings, Inc. has a beta of 0.619, which suggesting that the stock is 38.12% less volatile than S&P 500. In comparison Intuitive Surgical, Inc. has a beta of 1.653, suggesting its more volatile than the S&P 500 by 65.303%.
-
Which is a Better Dividend Stock ZBH or ISRG?
Zimmer Biomet Holdings, Inc. has a quarterly dividend of $0.24 per share corresponding to a yield of 0.97%. Intuitive Surgical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zimmer Biomet Holdings, Inc. pays 27.05% of its earnings as a dividend. Intuitive Surgical, Inc. pays out -- of its earnings as a dividend. Zimmer Biomet Holdings, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios ZBH or ISRG?
Zimmer Biomet Holdings, Inc. quarterly revenues are $2.2B, which are smaller than Intuitive Surgical, Inc. quarterly revenues of $2.9B. Zimmer Biomet Holdings, Inc.'s net income of $137.9M is lower than Intuitive Surgical, Inc.'s net income of $799.5M. Notably, Zimmer Biomet Holdings, Inc.'s price-to-earnings ratio is 27.84x while Intuitive Surgical, Inc.'s PE ratio is 64.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zimmer Biomet Holdings, Inc. is 2.38x versus 18.17x for Intuitive Surgical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ZBHZimmer Biomet Holdings, Inc.2.38x 27.84x $2.2B $137.9M ISRGIntuitive Surgical, Inc.18.17x 64.00x $2.9B $799.5M
-
Which has Higher Returns ZBH or NMTC?
NeuroOne Medical Technologies Corp. has a net margin of 6.15% compared to Zimmer Biomet Holdings, Inc.'s net margin of -49.71%. Zimmer Biomet Holdings, Inc.'s return on equity of 5.61% beat NeuroOne Medical Technologies Corp.'s return on equity of -132.79%.
Company Gross Margin Earnings Per Share Invested Capital ZBHZimmer Biomet Holdings, Inc.56.23% $0.70 $20.5B NMTCNeuroOne Medical Technologies Corp.54.2% -$0.03 $6.6M -
What do Analysts Say About ZBH or NMTC?
Zimmer Biomet Holdings, Inc. has a consensus price target of $102.65, signalling upside risk potential of 3.95%. On the other hand NeuroOne Medical Technologies Corp. has an analysts' consensus of $2.30 which suggests that it could grow by 238.24%. Given that NeuroOne Medical Technologies Corp. has higher upside potential than Zimmer Biomet Holdings, Inc., analysts believe NeuroOne Medical Technologies Corp. is more attractive than Zimmer Biomet Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ZBHZimmer Biomet Holdings, Inc.6 17 2 NMTCNeuroOne Medical Technologies Corp.1 0 0 -
Is ZBH or NMTC More Risky?
Zimmer Biomet Holdings, Inc. has a beta of 0.619, which suggesting that the stock is 38.12% less volatile than S&P 500. In comparison NeuroOne Medical Technologies Corp. has a beta of 0.661, suggesting its less volatile than the S&P 500 by 33.892%.
-
Which is a Better Dividend Stock ZBH or NMTC?
Zimmer Biomet Holdings, Inc. has a quarterly dividend of $0.24 per share corresponding to a yield of 0.97%. NeuroOne Medical Technologies Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zimmer Biomet Holdings, Inc. pays 27.05% of its earnings as a dividend. NeuroOne Medical Technologies Corp. pays out -- of its earnings as a dividend. Zimmer Biomet Holdings, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios ZBH or NMTC?
Zimmer Biomet Holdings, Inc. quarterly revenues are $2.2B, which are larger than NeuroOne Medical Technologies Corp. quarterly revenues of $2.9M. Zimmer Biomet Holdings, Inc.'s net income of $137.9M is higher than NeuroOne Medical Technologies Corp.'s net income of -$1.4M. Notably, Zimmer Biomet Holdings, Inc.'s price-to-earnings ratio is 27.84x while NeuroOne Medical Technologies Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zimmer Biomet Holdings, Inc. is 2.38x versus 3.51x for NeuroOne Medical Technologies Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ZBHZimmer Biomet Holdings, Inc.2.38x 27.84x $2.2B $137.9M NMTCNeuroOne Medical Technologies Corp.3.51x -- $2.9M -$1.4M
-
Which has Higher Returns ZBH or NTRB?
Nutriband, Inc. has a net margin of 6.15% compared to Zimmer Biomet Holdings, Inc.'s net margin of -1118.87%. Zimmer Biomet Holdings, Inc.'s return on equity of 5.61% beat Nutriband, Inc.'s return on equity of -164.64%.
Company Gross Margin Earnings Per Share Invested Capital ZBHZimmer Biomet Holdings, Inc.56.23% $0.70 $20.5B NTRBNutriband, Inc.18.2% -$0.32 $7.8M -
What do Analysts Say About ZBH or NTRB?
Zimmer Biomet Holdings, Inc. has a consensus price target of $102.65, signalling upside risk potential of 3.95%. On the other hand Nutriband, Inc. has an analysts' consensus of $15.00 which suggests that it could grow by 238.6%. Given that Nutriband, Inc. has higher upside potential than Zimmer Biomet Holdings, Inc., analysts believe Nutriband, Inc. is more attractive than Zimmer Biomet Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ZBHZimmer Biomet Holdings, Inc.6 17 2 NTRBNutriband, Inc.1 0 0 -
Is ZBH or NTRB More Risky?
Zimmer Biomet Holdings, Inc. has a beta of 0.619, which suggesting that the stock is 38.12% less volatile than S&P 500. In comparison Nutriband, Inc. has a beta of 1.886, suggesting its more volatile than the S&P 500 by 88.601%.
-
Which is a Better Dividend Stock ZBH or NTRB?
Zimmer Biomet Holdings, Inc. has a quarterly dividend of $0.24 per share corresponding to a yield of 0.97%. Nutriband, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zimmer Biomet Holdings, Inc. pays 27.05% of its earnings as a dividend. Nutriband, Inc. pays out -- of its earnings as a dividend. Zimmer Biomet Holdings, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios ZBH or NTRB?
Zimmer Biomet Holdings, Inc. quarterly revenues are $2.2B, which are larger than Nutriband, Inc. quarterly revenues of $346.1K. Zimmer Biomet Holdings, Inc.'s net income of $137.9M is higher than Nutriband, Inc.'s net income of -$3.9M. Notably, Zimmer Biomet Holdings, Inc.'s price-to-earnings ratio is 27.84x while Nutriband, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zimmer Biomet Holdings, Inc. is 2.38x versus 22.11x for Nutriband, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ZBHZimmer Biomet Holdings, Inc.2.38x 27.84x $2.2B $137.9M NTRBNutriband, Inc.22.11x -- $346.1K -$3.9M
-
Which has Higher Returns ZBH or SYK?
Stryker Corp. has a net margin of 6.15% compared to Zimmer Biomet Holdings, Inc.'s net margin of 11.84%. Zimmer Biomet Holdings, Inc.'s return on equity of 5.61% beat Stryker Corp.'s return on equity of 15.17%.
Company Gross Margin Earnings Per Share Invested Capital ZBHZimmer Biomet Holdings, Inc.56.23% $0.70 $20.5B SYKStryker Corp.62.81% $2.20 $38.8B -
What do Analysts Say About ZBH or SYK?
Zimmer Biomet Holdings, Inc. has a consensus price target of $102.65, signalling upside risk potential of 3.95%. On the other hand Stryker Corp. has an analysts' consensus of $424.40 which suggests that it could grow by 11.62%. Given that Stryker Corp. has higher upside potential than Zimmer Biomet Holdings, Inc., analysts believe Stryker Corp. is more attractive than Zimmer Biomet Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ZBHZimmer Biomet Holdings, Inc.6 17 2 SYKStryker Corp.13 8 0 -
Is ZBH or SYK More Risky?
Zimmer Biomet Holdings, Inc. has a beta of 0.619, which suggesting that the stock is 38.12% less volatile than S&P 500. In comparison Stryker Corp. has a beta of 0.873, suggesting its less volatile than the S&P 500 by 12.679%.
-
Which is a Better Dividend Stock ZBH or SYK?
Zimmer Biomet Holdings, Inc. has a quarterly dividend of $0.24 per share corresponding to a yield of 0.97%. Stryker Corp. offers a yield of 0.89% to investors and pays a quarterly dividend of $0.88 per share. Zimmer Biomet Holdings, Inc. pays 27.05% of its earnings as a dividend. Stryker Corp. pays out 40.48% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios ZBH or SYK?
Zimmer Biomet Holdings, Inc. quarterly revenues are $2.2B, which are smaller than Stryker Corp. quarterly revenues of $7.2B. Zimmer Biomet Holdings, Inc.'s net income of $137.9M is lower than Stryker Corp.'s net income of $849M. Notably, Zimmer Biomet Holdings, Inc.'s price-to-earnings ratio is 27.84x while Stryker Corp.'s PE ratio is 45.27x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zimmer Biomet Holdings, Inc. is 2.38x versus 5.85x for Stryker Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ZBHZimmer Biomet Holdings, Inc.2.38x 27.84x $2.2B $137.9M SYKStryker Corp.5.85x 45.27x $7.2B $849M
-
Which has Higher Returns ZBH or TNDM?
Tandem Diabetes Care, Inc. has a net margin of 6.15% compared to Zimmer Biomet Holdings, Inc.'s net margin of -0.2%. Zimmer Biomet Holdings, Inc.'s return on equity of 5.61% beat Tandem Diabetes Care, Inc.'s return on equity of -121.88%.
Company Gross Margin Earnings Per Share Invested Capital ZBHZimmer Biomet Holdings, Inc.56.23% $0.70 $20.5B TNDMTandem Diabetes Care, Inc.57.67% -$0.01 $604.5M -
What do Analysts Say About ZBH or TNDM?
Zimmer Biomet Holdings, Inc. has a consensus price target of $102.65, signalling upside risk potential of 3.95%. On the other hand Tandem Diabetes Care, Inc. has an analysts' consensus of $27.27 which suggests that it could grow by 10.08%. Given that Tandem Diabetes Care, Inc. has higher upside potential than Zimmer Biomet Holdings, Inc., analysts believe Tandem Diabetes Care, Inc. is more attractive than Zimmer Biomet Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ZBHZimmer Biomet Holdings, Inc.6 17 2 TNDMTandem Diabetes Care, Inc.7 15 0 -
Is ZBH or TNDM More Risky?
Zimmer Biomet Holdings, Inc. has a beta of 0.619, which suggesting that the stock is 38.12% less volatile than S&P 500. In comparison Tandem Diabetes Care, Inc. has a beta of 1.683, suggesting its more volatile than the S&P 500 by 68.285%.
-
Which is a Better Dividend Stock ZBH or TNDM?
Zimmer Biomet Holdings, Inc. has a quarterly dividend of $0.24 per share corresponding to a yield of 0.97%. Tandem Diabetes Care, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zimmer Biomet Holdings, Inc. pays 27.05% of its earnings as a dividend. Tandem Diabetes Care, Inc. pays out -- of its earnings as a dividend. Zimmer Biomet Holdings, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios ZBH or TNDM?
Zimmer Biomet Holdings, Inc. quarterly revenues are $2.2B, which are larger than Tandem Diabetes Care, Inc. quarterly revenues of $290.4M. Zimmer Biomet Holdings, Inc.'s net income of $137.9M is higher than Tandem Diabetes Care, Inc.'s net income of -$589K. Notably, Zimmer Biomet Holdings, Inc.'s price-to-earnings ratio is 27.84x while Tandem Diabetes Care, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zimmer Biomet Holdings, Inc. is 2.38x versus 1.63x for Tandem Diabetes Care, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ZBHZimmer Biomet Holdings, Inc.2.38x 27.84x $2.2B $137.9M TNDMTandem Diabetes Care, Inc.1.63x -- $290.4M -$589K
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Buy
55
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Sell
50
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 35x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 29x
Alerts
Buy
77
RNG alert for Feb 21
RingCentral, Inc. [RNG] is up 34.37% over the past day.
Sell
9
FROG alert for Feb 21
JFrog Ltd. [FROG] is down 24.98% over the past day.
Buy
72
SNSE alert for Feb 21
Sensei Biotherapeutics, Inc. [SNSE] is up 23.81% over the past day.
